Keeping Kidneys Safe: Pharmacist's Role in Counseling High-Risk Patients on NSAID Use to Prevent Kidney Injury

Activity Details
  • Credit Amounts:
    • CME: 0.50
    • CPE: 0.50
  • Cost: Free
  • Release: Apr 23, 2018
  • Expires: Apr 22, 2021
  • Estimated Time to Complete:
    30 Minutes
  • System Requirements:
  • Average User Rating:
    (4 Ratings)


Amy Barton Pai Amy Barton Pai, PharmD, BCPS, FASN, FCCP
Chair, Pharmacy Working Group of the National Kidney Disease Education Program
Associate Professor, Clinical Pharmacy
University of Michigan College of Pharmacy
Ann Arbor, Michigan

Needs Statement

An estimated 36 million Americans use over-the-counter analgesics on a daily basis. These pain relievers include NSAIDs such as ibuprofen and naproxen and are widely available in large quantities not only in pharmacies but also at wholesale stores, gas stations, or convenience stores. Patients may not report using NSAIDS during medication reviews because they are over-the-counter. These highly accessible medications may seem innocuous but carry a significant risk of precipitating acute kidney injury (AKI). Episodes of AKI can lead to costly hospitalizations. Recently it has been recognized that episodes of AKI have long-term consequences increasing risk for progressive chronic kidney disease. Importantly, most cases of NSAID-induced AKI can be avoided by recognizing high-risk patients and counseling on the appropriate use of these medications. To address this need, the National Kidney Disease Education Program (NKDEP) developed this educational content for pharmacists on how to counsel high-risk patients to avoid NSAID use to prevent AKI. 

Target Audience

This activity is intended for healthcare professionals, especially pharmacists, who counsel patients taking NSAIDS.


Upon completion of this activity, the participant should be able to:

1. Describe how prescription and non-prescription drugs affect blood flow through the kidneys (hemodynamics);
2. Discuss clinical implications of acute kidney injury (AKI);
3. Describe patients at risk for NSAID-induced AKI;
4. Identify key opportunities for pharmacists in education and prevention of NSAID-induced AKI;
5. Identify educational tools to enhance counseling sessions with patients.


This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Kentucky College of Medicine, and National Kidney Disease Education Program, National Institutes of Health.. The University of Kentucky College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The University of Kentucky College of Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The University of Kentucky College of Medicine presents this activity for educational purposes only. Participants are expected to utilize their own expertise and judgment while engaged in the practice of medicine. The content of the presentations is provided solely by presenters who have been selected for presentations because of recognized expertise in their field.

ACGME Competencies

  • Patient care
  • Medical knowledge
  • Practice-based learning and improvement
  • Interpersonal and communication skills

ACPEThe University of Kentucky College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

This knowledge-based activity has been assigned UAN 0022-9999-18-069-H01-P and will award 0.50 contact hours (0.050 CEUs) of continuing pharmacy education credit in states that recognize ACPE providers.

Statements of participation will indicate hours and CEUs based on participation and will be issued online at the conclusion of the activity. Successful completion includes completing the activity, its accompanying evaluation and/or posttest (score 70% or higher) and requesting credit online at the conclusion of the activity. Credit will be uploaded to CPE Monitor, and participants may print a statement of credit or transcript from their NABP e-profile. The College complies with the Accreditation Standards for Continuing Pharmacy Education.

Faculty Disclosure

No speaker or content reviewer have any relevant financial relationships to disclose. 

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Content review confirmed that the content was developed in a fair, balanced manner free from commercial bias. Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.


This activity is jointly provided by the University of Kentucky and National Kidney Disease Education Program, National Institutes of Health.

CE Content Concerns


Concerns or complaints related to ACPE or ACCME standards may be submitted in writing to the Director of UK HealthCare CECentral by fax to 859-323-2920, or by mail to 2365 Harrodsburg Road, Ste B475, Lexington, KY 40504


  • The Director or his/her designee will review, investigate, forward and/or respond to complaints and will put forth a best effort to adjudicate the issue(s), along with CECentral staff members, within two (2) weeks of receipt of the grievance or complaint.
  • If needed, concerns, complaints, or grievances will be brought before the UK HealthCare CECentral Advisory Board.
  • Issues regarding activity content also will be reviewed and addressed by the Activity Director.
  • A written decision will be issued in a timely manner by the Director of UK HealthCare CECentral or his/herdesignee.
  • Grievances will be considered when planning future activities.

Appeal Procedure

  • Persons who wish to appeal a decision should address the appeal by email, fax or in writing to the Director of UK HealthCare CECentral within two (2) weeks of receipt of the response.
  • The Director will bring the appeal to the UK HealthCare CECentral Advisory Board.
  • The results of the appeal will be sent to the participant no later than two (2) weeks following the meeting of the board.